What is HC Wainwright’s Estimate for TNGX Q1 Earnings?

Tango Therapeutics, Inc. ( NASDAQ:TNGX – Free Report ) – Analysts at HC Wainwright issued their Q1 2026 earnings per share estimates for shares of Tango Therapeutics in a research note issued to investors on Monday, April 14th. HC Wainwright analyst R.

Burns anticipates that the company will post earnings of ($0.39) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $13.



00 target price on the stock. The consensus estimate for Tango Therapeutics’ current full-year earnings is ($1.19) per share.

HC Wainwright also issued estimates for Tango Therapeutics’ Q2 2026 earnings at ($0.37) EPS, Q3 2026 earnings at ($0.38) EPS and Q4 2026 earnings at ($0.

40) EPS. Tango Therapeutics Trading Down 6.9 % Tango Therapeutics stock opened at $1.

28 on Tuesday. The company has a market capitalization of $138.38 million, a price-to-earnings ratio of -1.

08 and a beta of 1.03. Tango Therapeutics has a 12 month low of $1.

11 and a 12 month high of $12.02. The stock’s 50 day moving average is $1.

84 and its 200-day moving average is $3.37. Institutional Trading of Tango Therapeutics A number of institutional investors have recently bought and sold shares of the business.

Dynamic Technology Lab Private Ltd bought a new position in shares of Tango Therapeutics during the fourth quarter worth approximately $33,000. Stonebrook Private Inc. bought a new position in Tango Therapeutics during the 4th quarter worth $34,000.

Ameriprise Financial Inc. acquired a new position in Tango Therapeutics in the 4th quarter valued at $35,000. Sherbrooke Park Advisers LLC bought a new stake in shares of Tango Therapeutics during the 4th quarter valued at $38,000.

Finally, Squarepoint Ops LLC acquired a new stake in shares of Tango Therapeutics during the 4th quarter worth $40,000. Institutional investors own 78.99% of the company’s stock.

Insider Buying and Selling at Tango Therapeutics In related news, CEO Barbara Weber sold 9,778 shares of the company’s stock in a transaction dated Tuesday, February 4th. The shares were sold at an average price of $2.99, for a total value of $29,236.

22. Following the transaction, the chief executive officer now directly owns 1,631,264 shares in the company, valued at approximately $4,877,479.36.

This represents a 0.60 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link .

Insiders have sold a total of 24,268 shares of company stock valued at $72,561 in the last ninety days. 6.30% of the stock is currently owned by corporate insiders.

About Tango Therapeutics ( Get Free Report ) Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. Read More Receive News & Ratings for Tango Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tango Therapeutics and related companies with MarketBeat.

com's FREE daily email newsletter ..